KRAS is implicated in many cancers including colorectal cancer, pancreatic cancer and non‐small cell lung cancer.4, 5, 6 Amino acid substitutions are driver mutations, occurring early in the carcinogenesis process.7 Thus, methods that identify KRAS mutations could enable detection of early‐stage cancer and subsequently inform the clinician of preferential treatment regimens. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.